Related Experiment Videos
Helicobacter pylori and NSAIDs--what interaction
1Division of Gastroenterology & Hepatology, University of New Mexico HSC and Veterans Administration Medical Center, Albuquerque, USA. denis.mccarthy2@med.va.gov
The European Journal of Surgery. Supplement. : = Acta Chirurgica. Supplement
|November 23, 2001
Summary
Helicobacter pylori infection worsens drug-induced gastritis and dyspeptic symptoms. Eradicating H. pylori benefits aspirin users and new NSAID users, but not long-term NSAID users.
Area of Science:
- Gastroenterology
- Pharmacology
- Microbiology
Background:
- The interaction between Helicobacter pylori (H. pylori) infection and NSAID use is complex and debated.
- H. pylori infection can influence the severity of gastritis and dyspeptic symptoms in drug users.
Purpose of the Study:
- To clarify the impact of H. pylori infection on NSAID-associated gastrointestinal issues.
- To evaluate the benefits of H. pylori eradication in different NSAID user groups.
Main Methods:
- The study reviews existing literature on H. pylori infection, Aspirin (ASA), and non-aspirin nonsteroidal anti-inflammatory drugs (NANSAIDs).
- It analyzes the effects on gastritis, dyspeptic symptoms, ulcer formation, and healing.
Main Results:
- H. pylori infection increases the severity of drug-associated gastritis and dyspeptic symptoms.
- While more ulcers are found in infected NSAID users, ulcers may heal faster with acid suppressive therapy.
- H. pylori eradication benefits aspirin users and those starting NANSAID therapy, but not long-term NANSAID users.
Conclusions:
- H. pylori eradication is recommended for aspirin users and new NANSAID users.
- For long-term NANSAID users, proton-pump inhibitor therapy is superior for ulcer healing, recurrence prevention, and complication management.
- H. pylori infection significantly impacts NSAID-associated gastrointestinal pathology, necessitating tailored treatment strategies.